Human plasma kallikrein inhibitors
US11685721B2 · kind B2 · utility
2Cited by
11References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 9, 2021 |
| Grant date | Jun 27, 2023 |
| Priority date | — |
| Expiry date | Nov 9, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compounds of formula Ias described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.